1.47
-0.0676(-4.39%)
Currency In USD
| Previous Close | 1.54 |
| Open | 1.57 |
| Day High | 1.6 |
| Day Low | 1.4 |
| 52-Week High | 1.97 |
| 52-Week Low | 0.22 |
| Volume | 4.27M |
| Average Volume | 9.3M |
| Market Cap | 108.18M |
| PE | -2.23 |
| EPS | -0.66 |
| Moving Average 50 Days | 0.59 |
| Moving Average 200 Days | 0.52 |
| Change | -0.07 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $112.77 as of August 18, 2025 at a share price of $1.44. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $695.7 as of August 18, 2025 at a share price of $1.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
GlobeNewswire Inc.
Aug 12, 2025 8:00 PM GMT
- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs tha
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
GlobeNewswire Inc.
Jul 29, 2025 11:30 AM GMT
- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment -- Plasma and CSF biomarkers support zervi
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
GlobeNewswire Inc.
Jul 21, 2025 11:30 AM GMT
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL StudyPITTSBURGH, July 21, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (N